These Analysts Cut Their Forecasts On Johnson & Johnson After Q3 Results
Key takeaways
- JNJ beat earnings estimates and raised guidance, but analysts trimmed price targets, leading to a modest share price gain.
- Adjusted earnings $2.59 per share
- Sales $25.39 billion
- Full‑year earnings guidance $11.05‑$11.15
What happened
Johnson & Johnson (JNJ) reported third‑quarter earnings that beat expectations, with adjusted earnings of $2.59 per share versus the consensus estimate of $2.53. Sales rose 5.9% to $25.39 billion, topping the $25.25 billion forecast. The company lifted its full‑year adjusted earnings guidance to $11.05‑$11.15 per share and its sales outlook to $101.00‑$101.40 billion, both above analyst expectations.
Why it matters
The stronger-than‑expected earnings and higher guidance signal that JNJ’s portfolio of drugs, medical devices and consumer products is gaining traction, potentially supporting higher future cash flows. The upward revisions also reflect confidence in the company’s growth strategy, which could influence investor…
Short-term and longer-term
Short-term. JNJ’s stock is likely to trade within a tight range in the coming days as the market digests the earnings beat and guidance lift.
Longer-term. Over the next few months, investors should monitor JNJ’s progress in its high‑growth segments, particularly MedTech and oncology, to assess whether the company can maintain double‑digit growth.